论文部分内容阅读
近年来,左旋咪唑作为一种免疫疗法被广泛应用于各种癌肿的治疗。本文报告一组患各种癌肿病人用左旋咪唑与安慰剂治疗的对照试验,并作了免疫学评价。材料和方法 410例各种癌肿病人分别随机归入以下各项免疫学评价组:PPD(纯蛋白衍化物)组、DNCB(二硝基氯苯)组、Lipofundin清除组、血清免疫球蛋白测定组、血清补体测定组和测定E-玫瑰花结形成细胞(E-RFC)组。除血清免疫球蛋白组和Lipofundin清除试验组病人(92例)均用左旋咪唑治疗外,余各组中再将病人随机分左旋咪唑治疗组(共212例)和安慰剂对照组(共106例),治疗前后
In recent years, levamisole is widely used as a immunotherapy for the treatment of various types of cancer. This article reports a group of patients with various types of cancer treated with levamisole and placebo, and made an immunological evaluation. Materials and Methods 410 cases of various cancer patients were randomly assigned to the following immunological evaluation groups: PPD (pure protein derivative) group, DNCB (dinitrochlorobenzene) group, Lipofundin clearance group, serum immunoglobulin determination Group, the serum complement assay group, and the E-RFC group. In addition to levamisole treatment in patients with serum immunoglobulin and Lipofundin clearance test group (92 patients), the patients were randomly divided into levamisole treatment group (212 cases) and placebo control group (106 cases ), Before and after treatment